Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Ex Vivo Model in Cholestasis Research.

Karsten REH, Oosterhuis D, van Wijk LA, Olinga P.

Methods Mol Biol. 2019;1981:351-362. doi: 10.1007/978-1-4939-9420-5_23.

PMID:
31016666
2.

An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.

Kopper O, de Witte CJ, Lõhmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H, van Wijk LM, Revilla SA, Theeuwsen R, van de Ven M, van Roosmalen MJ, Ponsioen B, Ho VWH, Neel BG, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG, van Diest PJ, Witteveen PO, Jonges T, Bos JL, van Oudenaarden A, Zweemer RP, Snippert HJG, Kloosterman WP, Clevers H.

Nat Med. 2019 May;25(5):838-849. doi: 10.1038/s41591-019-0422-6. Epub 2019 Apr 22.

PMID:
31011202
3.

Peribiliary Glands Are Key in Regeneration of the Human Biliary Epithelium After Severe Bile Duct Injury.

de Jong IEM, Matton APM, van Praagh JB, van Haaften WT, Wiersema-Buist J, van Wijk LA, Oosterhuis D, Iswandana R, Suriguga S, Overi D, Lisman T, Carpino G, Gouw ASH, Olinga P, Gaudio E, Porte RJ.

Hepatology. 2019 Apr;69(4):1719-1734. doi: 10.1002/hep.30365. Epub 2019 Mar 5.

4.

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.

de Jonge MM, Auguste A, van Wijk LM, Schouten PC, Meijers M, Ter Haar NT, Smit VTHBM, Nout RA, Glaire MA, Church DN, Vrieling H, Job B, Boursin Y, de Kroon CD, Rouleau E, Leary A, Vreeswijk MPG, Bosse T.

Clin Cancer Res. 2019 Feb 1;25(3):1087-1097. doi: 10.1158/1078-0432.CCR-18-1443. Epub 2018 Nov 9.

PMID:
30413523
5.

Evolutionary dynamics of the kinetochore network in eukaryotes as revealed by comparative genomics.

van Hooff JJ, Tromer E, van Wijk LM, Snel B, Kops GJ.

EMBO Rep. 2017 Sep;18(9):1559-1571. doi: 10.15252/embr.201744102. Epub 2017 Jun 22.

6.

Performance of an Human Papillomavirus Test in Samples From Women With Histopathologically Confirmed Invasive Cervical Cancer.

Denny L, Mbatani N, Adams T, Van Wijk L, Behrens C, Tam T, Wright T Jr, Stoler M.

J Low Genit Tract Dis. 2016 Jul;20(3):e52-3. doi: 10.1097/LGT.0000000000000228. No abstract available.

PMID:
27224533
7.

Chromatin-Mediated Reversible Silencing of Sense-Antisense Gene Pairs in Embryonic Stem Cells Is Consolidated upon Differentiation.

Loos F, Loda A, van Wijk L, Grootegoed JA, Gribnau J.

Mol Cell Biol. 2015 Jul;35(14):2436-47. doi: 10.1128/MCB.00029-15. Epub 2015 May 11.

8.

A retrospective review of patients with stage IB2 cervical cancer treated with radical radiation versus radical surgery as a primary modality.

Alleyne-Mike K, van Wijk L, Hunter A.

Int J Gynecol Cancer. 2013 Sep;23(7):1287-94. doi: 10.1097/IGC.0b013e31829fb834.

PMID:
23863456
9.

Gestational trophoblastic neoplasia and human immunodeficiency virus infection: a 10-year review.

Tayib S, van Wijk L, Denny L.

Int J Gynecol Cancer. 2011 Dec;21(9):1684-91. doi: 10.1097/IGC.0b013e31822d8ffd.

PMID:
21997172
10.

Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.

Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, Hillege HL, Voors AA; BENEFICIAL investigators.

Eur J Heart Fail. 2011 Aug;13(8):899-908. doi: 10.1093/eurjhf/hfr067. Epub 2011 Jun 13.

11.

Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction.

Hartog JW, van de Wal RM, Schalkwijk CG, Miyata T, Jaarsma W, Plokker HW, van Wijk LM, Smit AJ, van Veldhuisen DJ, Voors AA.

Eur J Heart Fail. 2010 Apr;12(4):397-403. doi: 10.1093/eurjhf/hfq001. Epub 2010 Feb 12.

12.

Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial.

Willemsen S, Hartog JW, Hummel YM, Posma JL, van Wijk LM, van Veldhuisen DJ, Voors AA.

Eur J Heart Fail. 2010 Mar;12(3):294-300. doi: 10.1093/eurjhf/hfp207. Epub 2010 Jan 25.

13.

Reduced regional myocardial perfusion reserve is associated with impaired contractile performance in idiopathic dilated cardiomyopathy.

Tio RA, Slart RH, de Boer RA, van der Vleuten PA, de Jong RM, van Wijk LM, Willems T, Lubbers DD, Voors AA, van Veldhuisen DJ.

Neth Heart J. 2009 Dec;17(12):470-4.

14.

Chemoradiation in advanced vulval carcinoma.

Rogers LJ, Howard B, Van Wijk L, Wei W, Dehaeck K, Soeters R, Denny LA.

Int J Gynecol Cancer. 2009 May;19(4):745-51. doi: 10.1111/IGC.0b013e3181a13021.

PMID:
19509582
15.

Influence of renal dysfunction on the pharmacokinetics of the selective Na+/H+ exchange inhibitor EMD 87 580 in patients with chronic heart failure.

Smilde TD, Linssen GC, Gallemann D, Kuhn T, Machnig T, Mol PG, Hillege HL, Van Wijk LM, Van Dijk RB, Van Veldhuisen DJ.

Int J Clin Pharmacol Ther. 2005 Nov;43(11):507-16.

PMID:
16300166
16.

The role of neurosurgery in the treatment of cerebral metastases from choriocarcinoma: a report of two cases.

Semple PL, Denny L, Coughlan M, Soeters R, Van Wijk L.

Int J Gynecol Cancer. 2004 Jan-Feb;14(1):157-61.

PMID:
14764045
17.

Impairment of myocardial blood flow reserve in patients with asymptomatic left ventricular dysfunction: effects of ACE-inhibition with perindopril.

van den Heuvel AF, Blanksma PK, Siebelink HM, van Wijk LM, Boomsma F, Vaalburg W, Crijns HJ, van Veldhuisen DJ.

Int J Cardiovasc Imaging. 2001 Oct;17(5):353-9.

PMID:
12025949
18.

Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure.

Tjeerdsma G, van Wijk LM, Molhoek GP, Boomsma F, Haaksma J, van Veldhuisen DJ.

Cardiovasc Drugs Ther. 2001 Mar;15(2):139-45. Erratum in: Cardiovasc Drugs Ther 2002 Jan;16(1):79.

PMID:
11669407
19.

Autonomic dysfunction in patients with mild heart failure and coronary artery disease and the effects of add-on beta-blockade.

Tjeerdsma G, Szabó BM, van Wijk LM, Brouwer J, Tio RA, Crijns HJ, van Veldhuisen DJ.

Eur J Heart Fail. 2001 Jan;3(1):33-9.

20.

Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.

Vos MA, Golitsyn SR, Stangl K, Ruda MY, Van Wijk LV, Harry JD, Perry KT, Touboul P, Steinbeck G, Wellens HJ.

Heart. 1998 Jun;79(6):568-75.

21.

Is there an effect of perioperative blood transfusion on the outcome of radical hysterectomy with lymphadenectomy for cervical cancer in South Africa?

Wolterbeek JH, Soeters R, Van Wijk L, Van der Velde EA, Peters AA.

Eur J Gynaecol Oncol. 1998;19(5):458-63.

PMID:
9863912
22.

Hormone replacement therapy--1997.

Nevin J, Denny L, Dehaeck K, van Wijk L, Keating P, Soeters R.

S Afr Med J. 1997 Nov;87(11):1552. No abstract available.

PMID:
9472283
23.

Structure characterization of the central repetitive domain of high molecular weight gluten proteins. II. Characterization in solution and in the dry state.

Van Dijk AA, De Boef E, Bekkers A, Van Wijk LL, Van Swieten E, Hamer RJ, Robillard GT.

Protein Sci. 1997 Mar;6(3):649-56.

24.

Structure characterization of the central repetitive domain of high molecular weight gluten proteins. I. Model studies using cyclic and linear peptides.

Van Dijk AA, Van Wijk LL, Van Vliet A, Haris P, Van Swieten E, Tesser GI, Robillard GT.

Protein Sci. 1997 Mar;6(3):637-48.

25.

Primary chemotherapy with bleomycin, ifosfamide and cisplatinum (BIP) followed by radiotherapy in the treatment of advanced cervical cancer. A pilot study.

Nevin J, Bloch B, Van Wijk L, Soeters R, Dehaeck K, Ball H, Denny L.

Eur J Gynaecol Oncol. 1995;16(1):30-5.

PMID:
7538080
26.

Hemodynamic effects of the new antiarrhythmic agent restacorin in patients with normal and decreased left ventricular function.

Tuininga YS, Crijns HJ, Oosterhuis B, Wiesfeld AC, van Wijk LM, Albronda F, de Bruin H, Jonkman JH, Kozma C, Lie KI.

J Cardiovasc Pharmacol. 1994 Mar;23(3):408-14.

PMID:
7515984
27.

Flecainide: long-term effects in patients with sustained ventricular tachycardia or ventricular fibrillation.

van Wijk LM, Crijns HJ, Kingma HJ, van Gilst WH, van Gelder IC, Wesseling H, Lie KI.

J Cardiovasc Pharmacol. 1990 Jun;15(6):884-91.

PMID:
1694910
28.

Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter.

Van Gelder IC, Crijns HJ, Van Gilst WH, Van Wijk LM, Hamer HP, Lie KI.

Am J Cardiol. 1989 Dec 1;64(19):1317-21.

PMID:
2511744
29.

Predictors of long-term success during closed-chest catheter ablation of the atrioventricular junction.

Lemery R, Brugada P, Della Bella P, Dugernier T, Den Dulk K, Talajic M, Van Wijk L, Wellens HJ.

Eur Heart J. 1989 Sep;10(9):826-32.

PMID:
2806281
30.

Electrophysiological properties of isradipine (PN200-110) in humans.

van Wijk LM, van den Toren WE, van Gelder I, Crijns HJ, Ruegg P, Lie KI.

J Cardiovasc Pharmacol. 1989 Sep;14(3):492-5.

PMID:
2476631
31.

Cardiac electrophysiologic properties of intravenous isradipine in patients with sick sinus syndrome.

van Wijk LM, van Gelder I, Crijns HJ, van den Toren EW, Lie KI, Rüegg PC.

Am J Med. 1989 Apr 17;86(4A):88-90.

PMID:
2523662
32.

Flecainide acetate in the treatment of supraventricular tachycardias: value of programmed electrical stimulation for long-term prognosis.

van Wijk LM, Crijns HJ, van Gilst WH, Wesseling H, Lie KI.

Am Heart J. 1989 Feb;117(2):365-9.

PMID:
2492738
33.

Effects of flecainide on the atrial defibrillation threshold.

Van Gelder IC, Crijns HJ, Van Gilst WH, De Langen CD, Van Wijk LM, Lie KI.

Am J Cardiol. 1989 Jan 1;63(1):112-4. No abstract available.

PMID:
2491771
34.

Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation.

van Wijk LM, den Heijer P, Crijns HJ, van Gilst WH, Lie KI.

J Cardiovasc Pharmacol. 1989 Jan;13(1):32-6.

PMID:
2468933
35.

Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens.

Crijns HJ, van Wijk LM, van Gilst WH, Kingma JH, van Gelder IC, Lie KI.

Eur Heart J. 1988 Jun;9(6):634-8.

PMID:
3137061
36.

Successful use of flecainide in atrial fibrillation with rapid ventricular rate in the Wolff-Parkinson-White syndrome.

Crijns HJ, den Heijer P, van Wijk LM, Lie KI.

Am Heart J. 1988 Jun;115(6):1317-21. No abstract available.

PMID:
3132032
37.

Abnormal pharmacokinetics of flecainide in a "nonresponder".

van Gelder IC, Crijns HJ, van Wijk LM, van Gilst WH, Lie KI.

Clin Cardiol. 1988 May;11(5):353-5.

38.

Haemodynamic and antiarrhythmic effects of intravenous flecainide acetate in chronic congestive heart failure.

Dunselman PH, Kingma JH, van Wijk LM, Dijk A, Wesseling H, Lie KI.

Drugs. 1985;29 Suppl 4:58-64.

PMID:
4006780
39.

Visual and manual examination of whole stools in plastic bags.

van Wijk L, Wieriks J.

Br Med J. 1977 May 14;1(6071):1284-5. No abstract available.

40.

Topically active corticosteroids. A quantitative evaluation of McKenzie's skin-blanching test.

Engel DJ, Marx AF, Rekker RF, van Wijk L.

Arch Dermatol. 1974 Jun;109(6):863-5. No abstract available.

PMID:
4830098
41.

Treatment of progressive systemic sclerosis (PSS) with penicillamine. Preliminary report of two cases.

Tio H, van Wijk L, de Haan E.

Acta Med Scand. 1973 May;193(5):477-80. No abstract available.

PMID:
4717327

Supplemental Content

Loading ...
Support Center